Tesla, Xpeng, Summit Therapeutics lead Monday's morning market cap stock movers

Monday's trading session has seen significant activity among stocks across different market capitalization ranges. Notably, Tesla (NASDAQ:TSLA ), Xpeng Inc (NYSE:XPEV ) and Summit Therapeutics PLC (NASDAQ:SMMT ) have experienced notable intraday price movements. As the market progresses, these stocks, alongside others from the mega-cap and large-cap categories, are shaping the day's financial narrative. Here's a look at some of the key stock movers, from the largest companies to those with smaller market valuations.

Mega-Cap Movers



Tesla (TSLA); sees continued momentum following better earnings/margins last week: 1.4% higher;





Large-Cap Stock Movers



Summit Therapeutics PLC (SMMT); PESG Releases Market Update: +5.54%MicroStrategy Inc (MSTR); gains on strength in Bitcoin ; +5.45%Ke Holdings Inc (BEKE); +5.65%Tencent Music Entertainment Group (NYSE:TME ); +4.57%Coinbase Global (NASDAQ:COIN ); +4.16%Xpeng Inc (XPEV); +8.4%NIO Inc (NIO); +8.94%Affirm Holdings (NASDAQ:AFRM ); +6.93%Carnival Corp-Exch (NYSE:CCL ); +3.97%Albemarle (NYSE:ALB ); +5.87%





Mid-Cap Stock Movers



Procept Biorobotics (PRCT); PROCEPT BioRobotics Reports Third Quarter 2024 Financial Results: +30.01%AltC Acquisition (OKLO); +23.86%NantKwest (NASDAQ:IBRX ); +21.05%Vera Therapeutics (VERA); +13.65%Miniso Group Holding Ltd (MNSO); +9.65%Ikonics Corp (WULF); +10.03%Yandex (NASDAQ:NBIS ); +10.27%DJ Transportation Average (DJT); +1.01%





Small-Cap Stock Movers



Monte Rosa Therapeutics (GLUE); Monte Rosa inks $150 million Novartis (SIX:NOVN ) deal for MRT-6160: +68.3%pSivida Corp (EYPT); EyePoint reports positive DURAVYU trial results for DME: +34.32%Revance The (RVNC); +26.06%Septerna Inc (SEPN); +18.89%Serve Robotics (SERV); +18.4%Nuscale Power (SMR); +15.89%Prothena Corporation PLC (PRTA); +17.65%Stratasys (NASDAQ:SSYS ); +14.35%nLIGHT Inc (NASDAQ:LASR ); +17.33%





For real-time, market-moving news, join Investing Pro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Source: Investing.com